According to the terms of the deal, the initial purchase price of about $250 million will be paid in cash and Signify stock. The Dallas-based company will also make additional contingent payments totaling up to $50 million based on Caravan's future performance.
ViVE 2022, powered by HLTH and CHIME, will convene top thought leaders who are shaping tech-enabled healthcare and addressing key issues in digital health innovation. Save $150 with code medcity150!
We are extending our INVEST 2022 Pitch Perfect deadline to Feb 11, 11:59 p.m. ET to allow interested startups to apply to the 4 tracks - PharmaTech, Diagnostics 2.0, Care Coordination and Value-Based Care, and Remote Patient Monitoring and Smart Devices. Slots are going fast so we encourage all startups - particularly those interested to apply in the PharmaTech and Diagnostics tracks to apply immediately. Selected startups will get to pitch LIVE on stage in front of VC judges. Here's the agenda for the INVEST conference.
By Michael Schroeder Thursday, February 10, 2022 6:33 PM
According to the terms of the deal, the initial purchase price of about $250 million will be paid in cash and Signify stock. The Dallas-based company will also make additional contingent payments totaling up to $50 million based on Caravan's future performance.
By Arundhati Parmar Thursday, February 10, 2022 4:16 PM
The latest piece of evidence comes from Included Health, which found that its telehealth platform helped lower the blood pressure of patients with hypertension over a 12-month period during the pandemic. The peer-reviewed study was published in Mayo Clinic Proceedings.
By Michael Schroeder Thursday, February 10, 2022 1:52 PM
Ada Health closed its Series B round after a $30 million extension round. International investors Farallon Capital, Red River West and Bertelsmann Investments provided the additional funds. This follows an initial Series B raise of $90 million last May, which was led by Bayer's investment arm.
By Frank Vinluan Thursday, February 10, 2022 1:32 PM
Natural killers cells are the focus of a growing number of companies pursuing next-generation cell therapies for cancer. Indapta Therapeutics focuses on a subset of this class of cancer-killing cells, and it aims to use them in combination with antibody drugs to boost efficacy.
By Frank Vinluan Thursday, February 10, 2022 9:00 AM
Eli Lilly is among the new investors joining the Series B round of Arkuda Therapeutics, a biotech developing a drug to treat a rare, inherited form of dementia. If the biotech's approach works, it could also have applications in other neurodegenerative conditions such as Alzheimer's and Parkinson's.
By Alison Darcy Thursday, February 10, 2022 9:00 AM
It's time to reject reliance on the availability of human therapists and explore digitally driven, personalized care, so that each person receives exactly what they need when they need it, preserving our precious pool of trained human therapists for those that need them most.
No comments